Shopping Cart 0
Cart Subtotal
USD 0

U.S. Stem Cell Inc (USRM) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

U.S. Stem Cell Inc (USRM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal function. The company's lead product MyoCell, is designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, to improve cardiac function in chronic heart failure patients. Its services includes the development of proprietary cell therapy products based on regenerative medicine and cell therapy training services, cell collection and cell storage services, sale of cell collection and treatment kits for humans and animals, and operation of a cell therapy clinic. U.S. Stem Cell is headquartered in Sunrise, Florida, the US.

U.S. Stem Cell Inc Key Recent Developments

Jul 10,2018: Stem Cells Shows Promise For Repairing Torn Meniscus

May 14,2018: Autologous Stem Cell Therapy May Hold Key to Regeneration

May 09,2018: U.S. Stem Cell Reports First Quarter Results

Apr 24,2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales

Apr 16,2018: USRM Reports 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

U.S. Stem Cell Inc-Key Facts 6

U.S. Stem Cell Inc-Key Employees 7

U.S. Stem Cell Inc-Key Employee Biographies 8

U.S. Stem Cell Inc-Major Products and Services 9

U.S. Stem Cell Inc-History 10

U.S. Stem Cell Inc-Locations And Subsidiaries 12

Head Office 12

Other Locations & Subsidiaries 12

Joint Venture 12

Section 2-Company Analysis 13

Company Overview 13

U.S. Stem Cell Inc-Business Description 14

U.S. Stem Cell Inc-Corporate Strategy 15

U.S. Stem Cell Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

U.S. Stem Cell Inc-Strengths 16

U.S. Stem Cell Inc-Weaknesses 17

U.S. Stem Cell Inc-Opportunities 18

U.S. Stem Cell Inc-Threats 19

U.S. Stem Cell Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's, Lifesciences Financial Deals and Alliances 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

U.S. Stem Cell Inc, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

May 14, 2018: Autologous Stem Cell Therapy May Hold Key to Regeneration 30

May 09, 2018: U.S. Stem Cell Reports First Quarter Results 31

Apr 24, 2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales 32

Mar 21, 2018: USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells 33

Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 35

Dec 01, 2017: Adipocell Stem Cell Therapy Shows Safety In A Wide Variety of Applications 36

Nov 01, 2017: U.S. Stem Cell Announces Clinical Expansion in U.S. Market 37

Oct 11, 2017: U.S. Stem Cell New Study Underscores the Safety of Autologous Stem Cell Therapy in Degenerative Diseases and Injuries 38

Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 39

Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 40

Section 6-Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

U.S. Stem Cell Inc, Performance Chart (2013-2017) 24

U.S. Stem Cell Inc, Ratio Charts 26

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28


List Of Table

List of Tables

U.S. Stem Cell Inc, Key Facts 6

U.S. Stem Cell Inc, Key Employees 7

U.S. Stem Cell Inc, Key Employee Biographies 8

U.S. Stem Cell Inc, Major Products and Services 9

U.S. Stem Cell Inc, History 10

U.S. Stem Cell Inc, Joint Venture 12

U.S. Stem Cell Inc, Key Competitors 20

U.S. Stem Cell Inc, Ratios based on current share price 21

U.S. Stem Cell Inc, Annual Ratios 22

U.S. Stem Cell Inc, Annual Ratios (Cont...1) 23

U.S. Stem Cell Inc, Interim Ratios 25

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

U.S. Stem Cell Inc, Recent Deals Summary 29

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

U.S. Stem Cell Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

St. Jude Medical LLC

Medtronic Plc

Edwards Lifesciences Corp

Corindus Vascular Robotics Inc

U.S. Stem Cell Inc (USRM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal function. The company's lead product MyoCell, is designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, to improve cardiac function in chronic heart failure patients. Its services includes the development of proprietary cell therapy products based on regenerative medicine and cell therapy training services, cell collection and cell storage services, sale of cell collection and treatment kits for humans and animals, and operation of a cell therapy clinic. U.S. Stem Cell is headquartered in Sunrise, Florida, the US.

U.S. Stem Cell Inc Key Recent Developments

Jul 10,2018: Stem Cells Shows Promise For Repairing Torn Meniscus

May 14,2018: Autologous Stem Cell Therapy May Hold Key to Regeneration

May 09,2018: U.S. Stem Cell Reports First Quarter Results

Apr 24,2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales

Apr 16,2018: USRM Reports 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

U.S. Stem Cell Inc-Key Facts 6

U.S. Stem Cell Inc-Key Employees 7

U.S. Stem Cell Inc-Key Employee Biographies 8

U.S. Stem Cell Inc-Major Products and Services 9

U.S. Stem Cell Inc-History 10

U.S. Stem Cell Inc-Locations And Subsidiaries 12

Head Office 12

Other Locations & Subsidiaries 12

Joint Venture 12

Section 2-Company Analysis 13

Company Overview 13

U.S. Stem Cell Inc-Business Description 14

U.S. Stem Cell Inc-Corporate Strategy 15

U.S. Stem Cell Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

U.S. Stem Cell Inc-Strengths 16

U.S. Stem Cell Inc-Weaknesses 17

U.S. Stem Cell Inc-Opportunities 18

U.S. Stem Cell Inc-Threats 19

U.S. Stem Cell Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's, Lifesciences Financial Deals and Alliances 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

U.S. Stem Cell Inc, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

May 14, 2018: Autologous Stem Cell Therapy May Hold Key to Regeneration 30

May 09, 2018: U.S. Stem Cell Reports First Quarter Results 31

Apr 24, 2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales 32

Mar 21, 2018: USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells 33

Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 35

Dec 01, 2017: Adipocell Stem Cell Therapy Shows Safety In A Wide Variety of Applications 36

Nov 01, 2017: U.S. Stem Cell Announces Clinical Expansion in U.S. Market 37

Oct 11, 2017: U.S. Stem Cell New Study Underscores the Safety of Autologous Stem Cell Therapy in Degenerative Diseases and Injuries 38

Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 39

Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 40

Section 6-Appendix 41

Methodology 41

Ratio Definitions 41

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

U.S. Stem Cell Inc, Performance Chart (2013-2017) 24

U.S. Stem Cell Inc, Ratio Charts 26

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28


List Of Table

List of Tables

U.S. Stem Cell Inc, Key Facts 6

U.S. Stem Cell Inc, Key Employees 7

U.S. Stem Cell Inc, Key Employee Biographies 8

U.S. Stem Cell Inc, Major Products and Services 9

U.S. Stem Cell Inc, History 10

U.S. Stem Cell Inc, Joint Venture 12

U.S. Stem Cell Inc, Key Competitors 20

U.S. Stem Cell Inc, Ratios based on current share price 21

U.S. Stem Cell Inc, Annual Ratios 22

U.S. Stem Cell Inc, Annual Ratios (Cont...1) 23

U.S. Stem Cell Inc, Interim Ratios 25

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27

U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28

U.S. Stem Cell Inc, Recent Deals Summary 29

Currency Codes 41

Capital Market Ratios 41

Equity Ratios 42

Profitability Ratios 42

Cost Ratios 43

Liquidity Ratios 43

Leverage Ratios 44

Efficiency Ratios 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

U.S. Stem Cell Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

St. Jude Medical LLC

Medtronic Plc

Edwards Lifesciences Corp

Corindus Vascular Robotics Inc